BR0309212A - Composição de dispersão sólida - Google Patents

Composição de dispersão sólida

Info

Publication number
BR0309212A
BR0309212A BR0309212-7A BR0309212A BR0309212A BR 0309212 A BR0309212 A BR 0309212A BR 0309212 A BR0309212 A BR 0309212A BR 0309212 A BR0309212 A BR 0309212A
Authority
BR
Brazil
Prior art keywords
solid dispersion
dispersion composition
solid
composition
methylthio
Prior art date
Application number
BR0309212-7A
Other languages
English (en)
Inventor
Niichiro Takano
Hiroyuki Kawashima
Yasuo Shinoda
Toshio Inagi
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of BR0309212A publication Critical patent/BR0309212A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

"COMPOSIçãO DE DISPERSãO SóLIDA". Uma composição sólida caracterizada por conter 2 benzil - 5 - (4 - clorofenil) - 6 - [4- (metiltio) fenil]- 2H - piperazin - 3 - ona, hidroxipropil metil celulose e polioxietileno poioxipropileno glicol. A composição de dispersão sólida se dissolve completamente na água e uma concentração de 2 - benzil - 5 - (4 - clorofenil) - 6 - [4 - (metiltio) fenil] - 2H - piridazin - 3 - ona que se dissolveu é mantida por um certo tempo. Logo, o composto melhorou a capacidade de absorção no sangue.
BR0309212-7A 2002-04-16 2003-04-15 Composição de dispersão sólida BR0309212A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37241602P 2002-04-16 2002-04-16
PCT/JP2003/004762 WO2003086405A1 (fr) 2002-04-16 2003-04-15 Composition de dispersion solide

Publications (1)

Publication Number Publication Date
BR0309212A true BR0309212A (pt) 2005-02-09

Family

ID=29250849

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309212-7A BR0309212A (pt) 2002-04-16 2003-04-15 Composição de dispersão sólida

Country Status (22)

Country Link
US (1) US6753330B2 (pt)
EP (1) EP1495759A4 (pt)
JP (1) JP4295629B2 (pt)
KR (1) KR20040101437A (pt)
CN (1) CN1291719C (pt)
AU (1) AU2003235156B2 (pt)
BR (1) BR0309212A (pt)
CA (1) CA2481595A1 (pt)
EA (1) EA007153B1 (pt)
HK (1) HK1082669A1 (pt)
HR (1) HRP20040959A2 (pt)
IL (2) IL164206A0 (pt)
IS (1) IS7488A (pt)
MX (1) MXPA04010174A (pt)
MY (1) MY128945A (pt)
NO (1) NO20044337L (pt)
NZ (1) NZ535541A (pt)
PL (1) PL372980A1 (pt)
TW (1) TWI319772B (pt)
UA (1) UA79610C2 (pt)
WO (1) WO2003086405A1 (pt)
ZA (1) ZA200407657B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096281A1 (ja) * 2003-04-29 2004-11-11 Kowa Co., Ltd. 溶出性に優れた超難水溶性薬物含有組成物及びその製造法
US20070021418A1 (en) * 2003-07-30 2007-01-25 Kowa Co., Ltd. Method of inhibiting production of osteopontin
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition
JP2006001859A (ja) * 2004-06-16 2006-01-05 Shiseido Co Ltd 絆創膏組成物
US20090005384A1 (en) * 2005-01-25 2009-01-01 Kowa Co., Ltd Method for Producing Adsorptive Porous Body
CN101242831A (zh) * 2005-08-31 2008-08-13 兴和株式会社 类风湿性关节炎的预防和/或治疗方法
WO2008064259A2 (en) * 2006-11-21 2008-05-29 Biokey, Inc. Solid dispersion composition comprising fluvastatin
JP2009155282A (ja) * 2007-12-27 2009-07-16 Kowa Co 固体分散体含有医薬組成物
DE102008047910A1 (de) * 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2019241077A1 (en) * 2018-06-11 2019-12-19 Abon Pharmaceuticals Llc. Oral eliglustat transmucosal delivery system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019239A1 (fr) * 1994-12-21 1996-06-27 Yamanouchi Pharmaceutical Co., Ltd. Composition solide a solubilite et absorbabilite ameliorees
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
JP3335132B2 (ja) * 1997-11-19 2002-10-15 興和株式会社 新規ピリダジン誘導体及びこれを有効成分とする医薬
EP2017266A1 (en) * 1997-11-19 2009-01-21 Kowa Co., Ltd. Pyridazine derivatives and medicines containing the same as effective ingredients
BR0014469A (pt) * 1999-10-04 2002-06-11 Asahi Chemical Ind Processo para melhorar a solubilidade de um derivado de amino álcool tricìclico, composição farmacêutica, processo para preparar a mesma, e, derivado de amino álcool tricìclico
JP2004131393A (ja) * 2002-10-08 2004-04-30 Kowa Co 易溶出性製剤

Also Published As

Publication number Publication date
HK1082669A1 (en) 2006-06-16
IL164206A0 (en) 2005-12-18
NO20044337L (no) 2004-10-12
IS7488A (is) 2004-10-04
TW200408671A (en) 2004-06-01
MXPA04010174A (es) 2005-02-03
MY128945A (en) 2007-03-30
EA200401377A1 (ru) 2005-06-30
CN1646128A (zh) 2005-07-27
HRP20040959A2 (en) 2004-12-31
UA79610C2 (en) 2007-07-10
AU2003235156B2 (en) 2007-07-05
WO2003086405A1 (fr) 2003-10-23
JPWO2003086405A1 (ja) 2005-08-18
AU2003235156B9 (en) 2003-10-27
IL164206A (en) 2008-04-13
PL372980A1 (en) 2005-08-08
NZ535541A (en) 2006-09-29
JP4295629B2 (ja) 2009-07-15
TWI319772B (en) 2010-01-21
AU2003235156A1 (en) 2003-10-27
KR20040101437A (ko) 2004-12-02
EP1495759A1 (en) 2005-01-12
EP1495759A4 (en) 2010-12-29
US20040019122A1 (en) 2004-01-29
CN1291719C (zh) 2006-12-27
CA2481595A1 (en) 2003-10-23
ZA200407657B (en) 2006-07-26
EA007153B1 (ru) 2006-08-25
US6753330B2 (en) 2004-06-22

Similar Documents

Publication Publication Date Title
BR0309212A (pt) Composição de dispersão sólida
AR058892A1 (es) Metodos para tratar lupus cutaneo con el uso de compuestos de aminoisoindolina
DE60034139D1 (de) Pharmazeutisch-aktive isoindolin-derivate
AR007002A1 (es) Composicion de una materia conteniendo una sal de aril-heterociclo y una ciclodextrina o una sal de inclusion del mismo en una ciclodextrina
FR2835252B1 (fr) Utilisation d'un compose inactivant la proteine kinase a dans une composition contenant un milieu cosmetiquement acceptable, pour eclaicir la peau
AR030245A1 (es) Composiciones de gel que contienen metronidazol
GT200600465A (es) Composición para detergente líquido
CY1109764T1 (el) Υποκατεστημενα βενζαζολια και χρηση αυτων ως αναστολεις κινασης raf
DE502004003688D1 (de) Pyrazolidin-1,2-dicarbonsäure-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
DK1476438T3 (da) Oxa- og thiadiazoler og deres anvendelse som metalloproteinaseinhibitorer
NO20005883D0 (no) Anvendelse av <alfa>-1-<beta>-integrin-reseptorinhibitorer og TGF-<beta>-1-inhibitorer i behandling av nyresykdom
BR0314070A (pt) Métodos para a verificação de movimento de fluido
AU2003238475A1 (en) 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses
AR043251A1 (es) Formulaciones de esteroides para tratar personas que sufren de transtornos oculares
BR0016971A (pt) Método aperfeiçoado para ansiedade
PE20090320A1 (es) Derivados de piperidina-amida
IS8279A (is) Stöðug kristallskennt form af bífeprúnox mesílati(7-[4-([1,1'-bífenýl]-3-ýlmetýl)-1-píperasínýl]-2(3H)-bensoxasólón mónómetansúlfónat
ATE254457T1 (de) Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil
AR056454A1 (es) Mezclas pesticidas
ATE364373T1 (de) Kosmetische zusammensetzungen enthaltend ein copolymer aus methacrylsäure, cyclodextrin und ein tensid sowie deren verwendungen
DE112007001918A5 (de) Beschichtungs-, Klebe- und Imprägniermittel, insbesondere als Bau- und Restaurationsmaterial
AR051727A1 (es) Formulacion oral de liberacion inmediata de una sustancia activa poco soluble en agua
PE20060443A1 (es) Bencimidazoles y derivados de 1,2,4-triazina como agentes antiparasitarios
DE50106936D1 (de) Lösung zur Konservierung menschlicher Leberzellen, konservierte Leberzelle, und ihre Verwendung
AR043250A1 (es) Derivados de triazol como agentes insecticidas y antihelminticos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 8A E 9A ANUIDADES.